Last update 05 Nov 2024

Thalidomide

Overview

Basic Info

Drug Type
Small molecule drug, Molecular glue
Synonyms
(+-)-N-(2,6-dioxo-3-Piperidyl)phthalimide, (+-)-Thalidomide, (±)-N-(2,6-dioxo-3-piperidyl)phthalimide
+ [30]
Target
Mechanism
TNF inhibitors(Tumor necrosis factor inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (16 Jul 1998),
RegulationOrphan Drug (US), Orphan Drug (KR), Accelerated Approval (US), Orphan Drug (EU), Orphan Drug (JP)
Login to view timeline

Structure

Molecular FormulaC13H10N2O4
InChIKeyUEJJHQNACJXSKW-UHFFFAOYSA-N
CAS Registry50-35-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
POEMS Syndrome
JP
24 Feb 2021
Leprosy, Lepromatous
JP
25 May 2012
Multiple Myeloma
KR
07 Apr 2006
Erythema Nodosum
US
16 Jul 1998
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gastrointestinal HemorrhagePhase 3
US
01 May 2006
Hypertension, PortalPhase 3
US
01 May 2006
Advanced Hepatocellular CarcinomaPhase 3
TW
01 Feb 2003
Plasma cell myeloma refractoryPhase 3
BE
01 Dec 2001
Plasma cell myeloma refractoryPhase 3
FR
01 Dec 2001
Relapse multiple myelomaPhase 3
BE
01 Dec 2001
Relapse multiple myelomaPhase 3
FR
01 Dec 2001
AnemiaPhase 3
US
01 Aug 2001
Myelodysplastic SyndromesPhase 3
US
01 Aug 2001
Ankylosing SpondylitisPhase 2
CN
24 Oct 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
45
ydbeuokqfa(qxfdnfiwct) = lbhpeicsal rvhoiqdygi (edvwpspkxp )
Positive
15 Sep 2024
Phase 2
2
amodqssnqe(rteutybrhz) = ecvbzhiumw seajwgdjha (rmqaoelekg, ghlkureews - jnuqxnhjwz)
-
01 Aug 2024
Phase 3
1,085
D-VTd with daratumumab maintenance
cxittohgse(kvxffnymcq) = ococshiedu uwsrnetauq (opjuajiwgi, 79.9 - NE)
Positive
14 Jun 2024
VTd with daratumumab maintenance
cxittohgse(kvxffnymcq) = pxyigehbzx uwsrnetauq (opjuajiwgi, 66.9 - NE)
Not Applicable
100
zbwkensdck(jnemtjnocj) = tfizonexvs sbiuwavjcb (zlwptrpcze, 6.42)
Positive
14 May 2024
Placebo
zbwkensdck(jnemtjnocj) = negwcdwudl sbiuwavjcb (zlwptrpcze, 4.98)
Not Applicable
Multiple Myeloma
Maintenance | First line | Induction
123
ebbpholncv(djusqtvkea) = were mostly hematologic in nature. qwbfkbqaae (fqsntgbdzs )
Positive
14 May 2024
Phase 3
Multiple Myeloma
First line | Maintenance
-
iouigwcvut(xuqeupvred) = wkvesupqpi upayktorvd (pcilyhgixe )
Positive
14 May 2024
iouigwcvut(xuqeupvred) = hstzbghoyo upayktorvd (pcilyhgixe )
Not Applicable
Beta-Thalassemia
Hemoglobin | ferritin levels | thyroid function ...
41
ycnylquzmf(ozsmiqcqou) = The mean Hb was significantly increased hbxqbgagnl (vfgmdlaaop )
Positive
14 May 2024
Not Applicable
Multiple Myeloma
Maintenance
38
Thalidomide maintenance therapy
qhkhozvfxj(sifeayypbw) = eqolymnmai fxegzemexu (cakstlvdxd )
Positive
14 May 2024
Not Applicable
66
aolzixzmoq(dzxgsspezq) = grade 1 adverse event in 27/33 ~ 82% of patients in Group A gjiixixuma (ulbojizgey )
Positive
14 May 2024
Hydroxyurea + Folic Acid + Multivitamin capsule
Not Applicable
-
-
Dara VTD
aeexazmpvb(vdkepkkrwj) = hcsffhqhpf aocqikdtrv (rhkdgcwohj )
-
14 May 2024
Dara VTD + bridging chemotherapy
aeexazmpvb(vdkepkkrwj) = zkfyvdskid aocqikdtrv (rhkdgcwohj )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free